Vassiliki Gastari

Treatment with bortezomib‐based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group

Eirini Katodritou, Evangelos Terpos, Charikleia Kelaïdi et al. · American Journal of Hematology · 2013 · 68 citations · Full text

Hematological Malignancy, Bortezomib‐based Regimens, Transplantation +15

Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: A report of the Greek myeloma study group in 97 patients

Eirini Katodritou, Evangelos Terpos, Argiris Symeonidis et al. · American Journal of Hematology · 2014 · 67 citations · Full text

Prognostic Factors, Surgical Oncology, Adjuvant Chemotherapy +16

Extramedullary (EMP) relapse in unusual locations in multiple myeloma: Is there an association with precedent thalidomide administration and a correlation of special biological features with treatment and outcome?

Eirini Katodritou, Vassiliki Gastari, Evgenia Verrou et al. · Leukemia Research · 2009 · 48 citations

Hematological Malignancy, Medicine, Unusual Locations +7

Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone: Do specific cytogenetic and immunophenotypic characteristics influence treatment outcome?

Eirini Katodritou, Evgenia Verrou, Vassiliki Gastari et al. · Leukemia Research · 2008 · 36 citations

Hematological Malignancy, Do Specific Cytogenetic, Medicine +9

Erythropoiesis stimulating agents are associated with reduced survival in patients with multiple myeloma

Eirini Katodritou, Evgenia Verrou, Christina Hadjiaggelidou et al. · American Journal of Hematology · 2008 · 31 citations

Immunology, Pathology, Aplastic Anemia +16